CUCART19
/ Prince of Wales Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 17, 2024
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
(clinicaltrials.gov)
- P2 | N=20 | Recruiting | Sponsor: Chi Kong Li
New P2 trial • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 1
Of
1
Go to page
1